$eypt
$EYPT sees a surge in engagements on X, driven by discussions around institutional buying and a promising cancer drug development. The community is buzzing with positive sentiment.
About $eypt
$EYPT refers to the digital ecosystem and community surrounding a decentralized social media platform.
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Month: [-------] +32%
[--] Months: [-------] +27%
[--] Year: [---------] -3.90%
1-Year High: [-------] on 2025-03-05
1-Year Low: [--] on 2025-05-04
Engagements by network (24h): Reddit: [--] X: [-----]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-25
1-Year Low: [--] on 2025-10-09
Mentions by network (24h): Reddit: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $eypt in the last [--] hours which is up 18% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-10-05
The most influential creators that mention $eypt in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @plainyogurt21 | [--] | [-----] | [--] | [-----] |
| @Quantumup1 | [--] | [-----] | [--] | [---] |
| @semodough | [--] | [------] | [--] | [---] |
| @Mikeptyg | [--] | [--] | [--] | [--] |
| @seedytx19 | [--] | [-----] | [--] | [--] |
| @adamfeuerstein | [--] | [-------] | [--] | [--] |
| @CamillusMiura | [--] | [---] | [--] | [--] |
| @Barmon81512 | [--] | [--] | [--] | [--] |
| @WolfOfPathogens | [--] | [--] | [--] | [--] |
Sentiment: 67%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 67%
Daily Average: 85%
[--] Month: 67% +10%
[--] Months: 67% -8%
[--] Year: 67% -23%
1-Year High: 100% on 2025-02-19
1-Year Low: 11% on 2025-12-02
Most Supportive Themes:
- Strong Institutional Ownership and Insider Buying: (50%) The stock is trading at a significant discount to its cash value, with 87.7% institutional ownership and a recent insider buy of $6.35 million, indicating strong confidence from major investors.
- Promising Phase [--] Cancer Drug Development: (50%) The company is advancing a Phase [--] cancer drug, which represents a significant potential catalyst for growth and value appreciation.
Most Critical Themes:
Top $eypt Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"Key questions: $EYPT $OCUL Summarizing this all up here are the common questions you may have and my answers What about EYPT and their paper saying IC50 is all you need Basic pharmacology disagrees and the assays they used show inferiority of VEGF a model I dont trust. The Real world NPDR data and pharmacology beg to differ. Whats the upside How did you get there Eylea HD's only selling point is durability. Patients want durability. If this works the TKIs WILL sell well. Theyll price at a premium to VEGF likely at 2-3x Eylea to match their pricing. 40% discontinuation rates over time -they"
X Link @plainyogurt21 2026-02-15T13:41Z [----] followers, [----] engagements
"$EYPT $OCUL I played football throughout high school but stopped before college so I didnt stick with it long enough to get CTE. Instead I chose to look at $OCUL as my first foray into an ophthalmology readout. Boy its given me enough brain damage for a lifetime. We wanted to drop it this weekend pre readout. But hey Friday -Tuesday works with me. OCUL has an upcoming readout for SOL-1 in wet AMD. The design is odd. Patients with 20/80+ vision get two loading doses of eylea 2mg have to gain [--] letters and then are randomized to a single dose of Eylea 2mg or Axpaxli. Then we measure rescue"
X Link @plainyogurt21 2026-02-15T13:41Z [----] followers, 17.7K engagements
"$CRVS Tregs are pretty integral in inducing that durative effect You can see it in the $NKTR and $CRVS data The difference is the speed of the responses: $CRVS is reaching $NKTR W16 response at W4 & [--] (don't kill me I know it's a small sample size but $CRVS is also doing this in a population that includes 40-50% dupi and JAK failures not a fully naive pt pop so gotta give credit to that) Which makes sense MOA wise #Rezpeg is only affecting the Treg side of the treg/teff equation so to get it to balance you have to dose more and for a longer period (That's why they're extending the induction"
X Link @tradingsssss 2026-02-13T07:17Z [----] followers, 10.5K engagements
"$CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing signals that you can get durative efficacy" $NKTR $KYMR $EVMN also mentioned : Mizuho Senior Biotech Analyst @soowannaway shares his take on three key biotech trials that are scheduled to read out soon and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video: https://t.co/gnwTp8KeAW https://t.co/ktZtIrypkA : Mizuho Senior Biotech Analyst"
X Link @HOThomasWPhelps 2026-02-13T05:41Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing